Novoic develops AI-enabled software aimed at earlier detection of Alzheimer's disease within 10 minutes using speech-based cognitive testing. The company's technology detects subtle cognitive impairment and Alzheimer's neuropathology by analyzing how people speak.

Novoic's mission is to scale access to early detection of Alzheimer's disease, especially in underserved communities, through a low-burden, high-usability, and device-independent approach. Their automated speech-based tests are designed for real-world use, providing high data integrity and accuracy comparable to plasma tests in predicting Alzheimer's pathology.

The company's advanced AI models and proprietary large audio and language models are trained to detect clinically relevant patterns for early-stage Alzheimer's, including mild cognitive impairment and preclinical disease. Novoic supports over 50 medical institutions and clinical trials for biomarker-confirmed Alzheimer's, offering tools like the Novoic Storyteller, Dashboard, and Speech API to facilitate digital screening and monitoring at scale.

Novoic offers automated, self-assessment audio-verbal tests that work on any smart device via a browser-based platform. Their solutions maximize data integrity with quality control systems and state-of-the-art automated speech recognition. The software is secure with integrated HIPAA/GDPR compliance and designed for easy implementation and monitoring of patient funnels across multi-site trials.